Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA. · 2017
Read Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. by Zhang J, Cunningham JJ, Brown JS, Gatenby RA. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5703947.txt.
Introduction
Zhang and co-authors apply evolution theory to prostate cancer treatment. Their study concerns metastatic cancer that no longer responds to hormone control. The drug abiraterone blocks an enzyme the body uses to make testosterone. With steady dosing, resistance leads to failure at a median of about 16.5 months.
The team built a game theory model with three competing cell types. Steady dosing strongly favored drug-proof cells in the model. Adaptive therapy turns the drug on and off based on tumor response. That kept drug-proof cells in check and cut total drug use. In a pilot trial, 10 of 11 patients kept stable tumor cycles. Median time to progression reached at least 27 months, with 47 percent of the standard dose.
Catalog record
| CREATOR | Zhang J, Cunningham JJ, Brown JS, Gatenby RA. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer By Jingsong Zhang, Jessica J Cunningham, Joel S Brown, Robert A Gatenby Published in: Nature Communications DOI: 10.1038/s41467-017-01968-5 ABSTRACT Abstract Abiraterone treats metastatic castrate-resistant prostate cancer by inhibiting CYP17A, an enzyme for testosterone auto-production. With standard dosing, evolution of resistance with treatment failure (radiographic progression) occurs at a median of ~16.5 months. We hypothesize time to progression (TTP) could be increased by integrating evolutionary dynamics into therapy. We developed an evolutionary game theory model using Lotka–Volterra equations with three competing cancer “species”: androgen dependent, androgen producing, and androgen independent. Simulations with standard abiraterone dosing demonstrate strong selection for androgen-independent cells and rapid treatment failure. Adaptive therapy, using patient-specific tumor dynamics to inform on/off treatment cycles, suppresses proliferation of androgen-independent cells and lowers cumulative drug dose. In a pilot clinical trial, 10 of 11 patients maintained stable oscillations of tumor burdens; median TTP is at least 27 months with reduced cumulative drug use of 47% of standard dosing. The outcomes show significant improvement over published studies and a contemporaneous population. INTRODUCTION Evolution of resistance is a common cause of cancer treatment failure and tumor progression but explicit incorporation of intratumoral Darwinian dynamics in therapeutic trials is rare1. In fact, the conventional treatment strategy, which administers cytotoxic drugs at maximum tolerated dose (MTD) until progression, can be evolutionarily unwise because it strongly selects for resistant phenotypes and eliminates potential competitors. These Darwinian dynamics—termed “competitive release”2—can lead to rapid proliferation of resistant populations. A number of recently developed treatment strategies have applied evolutionary principles to prolong tumor control by inhibiting the emergence of treatment-resistant populations3–6. These strategies7 typically exploit the evolutionary costs of synthesis, maintenance, and operation of the molecular machinery needed to survive treatment. The benefits of resistance exceed costs during therapy. However, in the absence of treatment, particularly in the resource-limited tumor microenvironment, this cost renders resistant cells less fit than sensitive phenotypes8. Thus, appropriately timed withdrawal of treatment can allow residual populations of sensitive cells to exploit their fitness advantage at the expense of the less-fit resistant phenotypes. While discontinuation of treatment allows tumor regrowth, the resistant subpopulation remains small so that retreatment with the same drug(s) remains effective (Fig. 1). [Figure: Illustration of the designed evolutionary dynamics in adaptive therapy. a,b The purple cells are sensitive to the treatment and the green cells are resistant. The graphs represent the simulated density of each population over time during treatment. The top row represents standard therapy in which the maximum tolerated dose is given continuously after initiation. The cells sensitive to treatment are eliminated quickly. This intensely selects for cells that are resistant to the treatment, in this case T− cells, and eliminates the competition effects of the T+ population, resulting in competitive release with rapid treatment failure and tumor progression. The bottom row represents an evolution-based strategy in which therapy is halted before all of the sensitive cells are eliminated. In the absence of therapy, the sensitive cells out-compete the resistant cells due to their fitness advantage. This “steers” the tumor back to the pretreatment so that it remains sensitive to treatment. The resistant cells, or T− population, will increase slightly with each cycle so that this treatment eventually fails. However, mathematical models demonstrate control may be durably maintained for up to 20 cycles - significantly longer than continuous therapy.] Evolution-based treatment strategies have successfully controlled breast and ovarian cancers, often indefinitely, in pre-clinical experiments2, 3, 9. However, translation to a clinical setting has remained elusive. Conceptually, therapy and the evolution of resistance represent an evolutionary game between the cancer and oncologist (not unlike a predator-prey game) and between the different cancer cell types10, 11. As a game, the cancer cells are the players, their heritable phenotypes their strategies, and payoffs take the form of proliferation and survival. A cancer cell’s survival and proliferation can be influenced by its own phenotype, the phenotypes of others and the overall abundances of the different cancer cell types12, 13. Mathematical models provide valuable tools for formulating hypotheses and for evaluating different scenarios pertaining to the interactions between cancer cell types and therapy14–16. Here, we focus on the treatment of metastatic prostate cancer (mPC). First-line treatment of mPC uses androgen deprivation therapy (ADT), but nearly all men progress to a metastatic castrate-resistant prostate cancer (mCRPC) stage. A common mechanism of resistance to ADT is increased expression of CYP17A117, 18, a key enzyme for androgen synthesis19, 20. This generates an autocrine loop that replenishes intratumoral testosterone concentrations. Abiraterone acetate, a CYP17A1 inhibitor, reduces PSA, and improves overall survival. In subjects who initially respond to abiraterone, median time to PSA progression ranges from 5.8 to 11.1 months, depending on the study and if docetaxel was previously administered20–23, and median time to radiographic progression is about 16.5 months. A previous trial (SWOG 9346) investigated intermittent ADT with goals of improving quality of life and delaying onset of hormone resistance24, 25. Patients with newly diagnosed castration sensitive mPC were randomized into continuous or intermittent ADT treatment. After a median follow up of 9.8 years, neither regimen proved superior. While this trial attempted to use evolutionary dynamics to improve treatment outcomes, our analysis found it lacked an explicit link between the treatment schedule and intratumoral evolutionary dynamics. For example, the protocol25 started with an 8-month “induction period” with continuous high-dose therapy. Treatment was discontinued only if PSA < 4ng/ml. In our computational model (see below), we found this trial design, by eliminating nearly all of the sensitive cells during the induction period, promoted competitive release virtually identical to continuous high-dose therapy. We suggest that the successful application of evolutionary principles to the clinical treatment of prostate cancer requires formal mathematical models that frame the complex, often non-linear, interactions that define response and resistance to therapy in individual patients. Here we present a methodology for integrating intratumoral Darwinian dynamics in the clinical treatment of mCRPC. We first define relevant intratumoral subpopulations based on their interactions with the critical treatment factor—testosterone. Observations of clinical specimens17 reveal three competing phenotypes: (i) T+ cells requiring exogenous androgen; (ii) TP (testosterone producing) cells expressing CYP17A1 and producing testosterone; and (iii) T− cells that are androgen-independent and resistant to abiraterone. We frame the population dynamics before and during abiraterone therapy using a game theoretic model built on evolutionary first principles with parameter estimates derived from clinically available data. Computer simulations of conventional MTD treatment were consistent with observed clinical outcomes with a rapid increase of resistant (T−) populations. The modeling results then demonstrated how an adaptive therapy treatment strategy synchronized with intratumoral evolutionary dynamics may prolong time to progression and substantially decrease total drug dose. The evolution-based strategy suggested by the model was then applied in a pilot clinical trial. Here we present the mathematical and computational methods used to integrate evolutionary dynamics into a clinical trial, and the results of an interim analysis of the trial cohort. RESULTS Model simulations Model simulations (Fig. 2) demonstrate that an untreated tumor will result in a large tumor volume as various mixes of TP, T+, and T− cells grow to lethal population sizes. First-line androgen deprivation therapy (ADT) targets the T+ population but not the TP or